AU2019378161B2 - Crystalline forms of a substituted imidazopyridine compound and use thereof as P2x3 modulator - Google Patents

Crystalline forms of a substituted imidazopyridine compound and use thereof as P2x3 modulator Download PDF

Info

Publication number
AU2019378161B2
AU2019378161B2 AU2019378161A AU2019378161A AU2019378161B2 AU 2019378161 B2 AU2019378161 B2 AU 2019378161B2 AU 2019378161 A AU2019378161 A AU 2019378161A AU 2019378161 A AU2019378161 A AU 2019378161A AU 2019378161 B2 AU2019378161 B2 AU 2019378161B2
Authority
AU
Australia
Prior art keywords
type
crystalline form
methyl
compound
theta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019378161A
Other languages
English (en)
Other versions
AU2019378161A1 (en
Inventor
Nathalie Chauret
Denis Garceau
Kemal Payza
Robert M. Wenslow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 3 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 3 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 3 Ltd filed Critical GlaxoSmithKline Intellectual Property No 3 Ltd
Publication of AU2019378161A1 publication Critical patent/AU2019378161A1/en
Assigned to GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 3) LIMITED reassignment GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 3) LIMITED Request for Assignment Assignors: BELLUS HEALTH COUGH INC.
Application granted granted Critical
Publication of AU2019378161B2 publication Critical patent/AU2019378161B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
AU2019378161A 2018-11-13 2019-11-12 Crystalline forms of a substituted imidazopyridine compound and use thereof as P2x3 modulator Active AU2019378161B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862760307P 2018-11-13 2018-11-13
US62/760,307 2018-11-13
PCT/IB2019/001199 WO2020099923A1 (en) 2018-11-13 2019-11-12 Crystalline forms of a substituted imidazopyridine compound and use thereof as p2x3 modulator

Publications (2)

Publication Number Publication Date
AU2019378161A1 AU2019378161A1 (en) 2021-06-03
AU2019378161B2 true AU2019378161B2 (en) 2025-01-30

Family

ID=70732059

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019378161A Active AU2019378161B2 (en) 2018-11-13 2019-11-12 Crystalline forms of a substituted imidazopyridine compound and use thereof as P2x3 modulator

Country Status (20)

Country Link
US (1) US20220002292A1 (https=)
EP (1) EP3880678B1 (https=)
JP (2) JP2022507251A (https=)
CN (1) CN113302191A (https=)
AU (1) AU2019378161B2 (https=)
CA (1) CA3119711A1 (https=)
DK (1) DK3880678T3 (https=)
ES (1) ES3033466T3 (https=)
FI (1) FI3880678T3 (https=)
HR (1) HRP20250864T1 (https=)
HU (1) HUE071480T2 (https=)
IL (1) IL282996A (https=)
LT (1) LT3880678T (https=)
MX (1) MX2021005424A (https=)
PL (1) PL3880678T3 (https=)
PT (1) PT3880678T (https=)
RS (1) RS66922B1 (https=)
SI (1) SI3880678T1 (https=)
SM (1) SMT202500237T1 (https=)
WO (1) WO2020099923A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL282087B2 (en) * 2018-10-10 2025-11-01 Bellus Health Cough Inc 4-(imidazo[1,2-a]pyridin-3-yl)-benzamide derivatives for treating pruritus
JP7578602B2 (ja) * 2019-02-25 2024-11-06 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド Ｐ２ｘ３修飾薬での治療
CN114085220B (zh) * 2020-06-22 2023-06-16 上海海雁医药科技有限公司 取代的吗啉-4-羧酸酯衍生物、其组合物及医药上的用途
EP4169921A4 (en) * 2020-06-29 2024-06-19 Wuhan LL Science and Technology Development Co., Ltd. Crystalline form of heterocyclic compound, preparation method therefor and application thereof
WO2022161462A1 (zh) * 2021-01-29 2022-08-04 上海海雁医药科技有限公司 吗啉衍生物及其药物组合物和用途
WO2025140586A1 (zh) * 2023-12-29 2025-07-03 人福医药集团股份公司 一种p2x3受体拮抗剂的固体分散体及其制备工艺
WO2025191081A1 (en) 2024-03-15 2025-09-18 Glaxosmithkline Intellectual Property (No.3) Limited Crystalline form of camlipixant
WO2025210540A1 (en) 2024-04-02 2025-10-09 Assia Chemical Industries Ltd. Solid state forms of camlipixant and process for preparation thereof
WO2026022326A1 (en) * 2024-07-25 2026-01-29 Glaxosmithkline Intellectual Property (No.3) Limited P2x3 antagonist formulation
JP2026049185A (ja) 2024-09-06 2026-03-18 キヤノン株式会社 撮像装置、撮像方法、及びコンピュータプログラム

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9598409B2 (en) * 2013-01-31 2017-03-21 Neomed Institute Imidazopyridine compounds and uses thereof
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9598409B2 (en) * 2013-01-31 2017-03-21 Neomed Institute Imidazopyridine compounds and uses thereof
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators

Also Published As

Publication number Publication date
PT3880678T (pt) 2025-05-22
MX2021005424A (es) 2021-06-15
EP3880678A1 (en) 2021-09-22
CN113302191A (zh) 2021-08-24
JP2022507251A (ja) 2022-01-18
AU2019378161A1 (en) 2021-06-03
SI3880678T1 (sl) 2025-08-29
EP3880678A4 (en) 2022-08-31
LT3880678T (lt) 2025-06-25
HRP20250864T1 (hr) 2025-09-26
EP3880678B1 (en) 2025-05-07
HUE071480T2 (hu) 2025-08-28
RS66922B1 (sr) 2025-07-31
WO2020099923A1 (en) 2020-05-22
FI3880678T3 (fi) 2025-08-01
IL282996A (en) 2021-06-30
US20220002292A1 (en) 2022-01-06
PL3880678T3 (pl) 2025-08-04
DK3880678T3 (da) 2025-06-10
JP2024153665A (ja) 2024-10-29
SMT202500237T1 (it) 2025-07-22
CA3119711A1 (en) 2020-05-22
ES3033466T3 (en) 2025-08-04

Similar Documents

Publication Publication Date Title
AU2019378161B2 (en) Crystalline forms of a substituted imidazopyridine compound and use thereof as P2x3 modulator
JP2025026857A (ja) 痛風または高尿酸血症を処置または予防するための化合物の結晶形態
TW201729812A (zh) 一種含有ｊａｋ激酶抑制劑或其可藥用鹽的醫藥組成物
KR20170095896A (ko) 페놀성 trpv1 작용제의 프로드러그
WO2004054574A1 (ja) 経口固形医薬
US20120141586A1 (en) Thrombin receptor antagonist and clopidogrel fixed dose tablet
EP4268816B1 (en) Oral solid preparation
JP2021532183A (ja) フェノール性ｔｒｐｖ１アゴニストのｐｅｇ化プロドラッグ
AU2020289738A1 (en) A pharmaceutical composition comprising an oxazine derivative and its use in the treatment or prevention of Alzheimer's Disease
EP4551573A1 (en) Crystalline forms of an s1p receptor modulator
AU2018325267B2 (en) Crystalline forms of compounds for preventing or treating sensory hair cell death
JP7271869B2 (ja) レボセチリジン含有錠剤
WO2017107857A1 (zh) 一种含有二胺衍生物或其盐的固体药物组合物
JP2020015690A (ja) レボセチリジン含有錠剤
EP4413987A1 (en) Antifibrotic composition
WO2026085383A1 (en) Crystalline forms of an nlrp3 modulator
JP2025522917A (ja) Ｔｙｋ２阻害剤の結晶形態
HK40099642A (en) Oral solid preparation
JP2007297348A (ja) エバスチンを含有する錠剤

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 3) LIMITED

Free format text: FORMER APPLICANT(S): BELLUS HEALTH COUGH INC.

FGA Letters patent sealed or granted (standard patent)